Medicine & Life Sciences
Imatinib Mesylate
100%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
87%
Protein-Tyrosine Kinases
57%
Tyrosine
43%
Phosphotransferases
38%
Acute Myeloid Leukemia
36%
Phosphorylation
31%
Mutation
29%
Myeloid Cells
23%
Leukemia
23%
Leukemia, Myeloid, Chronic Phase
22%
Proteins
21%
Neoplasms
19%
src Homology Domains
18%
Cell Line
18%
Proteogenomics
18%
Philadelphia Chromosome
17%
Cytogenetics
17%
Therapeutics
15%
Dasatinib
15%
ponatinib
13%
Signal Transduction
13%
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13%
Blast Crisis
12%
Interleukin-3
9%
bcr-abl Fusion Proteins
9%
Interferons
9%
Phosphotyrosine
9%
Blood Platelets
9%
Growth
9%
In Vitro Techniques
8%
Pharmaceutical Preparations
8%
Phosphatidylinositol 3-Kinase
7%
Oncogenes
7%
Colony-Stimulating Factor Receptors
7%
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
7%
T-Lymphocytes
7%
Platelet-Derived Growth Factor Receptors
7%
Thrombopoietin
6%
Granulocyte-Macrophage Colony-Stimulating Factor
6%
B-Lymphocytes
6%
Stem Cell Factor
6%
Drug Resistance
6%
Leukemia, Neutrophilic, Chronic
6%
tandutinib
5%
Syk Kinase
5%
Genes
5%
T-Cell Antigen Receptor
5%
venetoclax
5%
Hematologic Neoplasms
5%
Chemical Compounds
Tyrosine
43%
Imatinib
32%
Mutation
20%
Protein
19%
Tyrosine Kinase Inhibitor
18%
Cytogenetics
15%
Colony Stimulating Factor
13%
Oncogenic
7%
Phosphotransferase Inhibitor
7%
Resistance
7%
Signal Transduction
6%